The drug is now approved for treating people with an LVEF of at least 40%, with or without chronic kidney disease.

Ahmedabad: CORONA Remedies has announced the acquisition of seven brands from the pharmaceutical division of Bayer in ...

The approval was supported by data from the randomized, double-blind, placebo-controlled, event-driven phase 3 FINEARTS-HF study.

ERA Congress 2025 marked a pivotal moment in nephrology this year, bringing together over 9,000 global experts to explore ...

Improving Global Outcomes (KDIGO) group has updated chronic kidney disease treatment guidelines to help slow disease progression in adults. A JAMA article published Wednesday summarized the revised ...

Just over two years into Anderson's tenure, Bayer's board has decided to extend his contract by three years to 31st March, 2029, with company chairman Norbert Winkeljohann saying: "We're starting to ...